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Abstract
T cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy with dismal overall 
prognosis, exhibiting up to a 25% relapse rate, mainly due to the absence of non-cytotoxic targeted 
therapy options. Despite the fact that drugs targeting the function of key epigenetic factors have 
been approved in the context of hematopoietic disorders1 and the recent identification of mutations 
affecting chromatin modulators in a variety of leukemias2,3, “epigenetic” drugs are not currently 
used for TALL treatment. Recently, we described a tumor suppressor role of the polycomb 
repressive complex 2 (PRC2) in this tumor4. Here we sought out to delineate the role of histone 3 
lysine 27 (H3K27) demethylases, JMJD3 and UTX. We show that JMJD3 is essential for initiation 
and maintenance of disease, as it controls important oncogenic gene targets through the 
modulation of H3K27 methylation. In contrast, UTX acts a tumor suppressor and frequently 
genetically inactivated in T-ALL. Moreover, we demonstrate that the small molecule inhibitor 
GSKJ45 affects T-ALL growth, by targeting JMJD3 activity. These findings show that two 
proteins with similar enzymatic function can play opposing roles in the context of the same 
disease and pave the way for the use of a new category of epigenetic inhibitors in hematopoietic 
malignancies.
In recent studies others and we revealed a key tumor-suppressor function for PRC2 that 
catalyzes methylation of H3K272,4,29. Since net H3K27me3 levels are dictated by the 
balance between histone methylation and active demethylation, we hypothesized that 
removal of methyl groups from H3K27 is also an important process in T-ALL progression. 
We therefore investigated possible roles for H3K27 demethylases in T-ALL (see also 
Supplementary File 1 for extended Introduction); Ubiquitously transcribed tetratricopeptide 
Repeat X-linked Protein (UTX6,7, official symbol KDM6A) is a ubiquitously expressed 
protein that controls basal levels of H3K27me3 and induction of ectoderm and mesoderm 
differentiation8,9 and is essential for reprogramming10. Jumonji d3 (JMJD36,7, KDM6B) is 
induced upon inflammation11, viral and oncogenic stimuli12,13 controls neuronal and 
epidermal differentiation14,15 and inhibits reprogramming16. UTX is as a tumor suppressor 
in several solid tumors17,18,3,19,20. However, the roles of these two demethylases as direct 
modulators of the oncogenic state are largely uncharacterized12,13.
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We have generated and studied NOTCH1-induced T-ALL animal models4 (Fig. 1a), as 
activating mutations of NOTCH1 are a defining feature of this disease21. Jmjd3 mRNA and 
protein expression levels were significantly higher in leukemic cells when compared to 
untransformed CD4+/CD8+ control T cells that exhibit low levels of active Notch1 whereas 
Utx (and Ezh24) expression did not change significantly (Fig. 1b, c and Supplementary File 
2/Table 1) upon transformation. It was previously shown that NFkB controls JMJD3 
expression during inflammation11 and that NOTCH1 induces the NFkB pathway in T-
ALL22. Here, we were able to show increased expression of the p65 (Rela) subunit of NFkB 
and its binding-but not Notch1- on Jmjd3 control elements in T-ALL cells (Extended Data 
Fig. 1a, b). Modulation of the levels of intracellular NOTCH1 or activity of NFkB pathway 
decreased significantly the amounts of NFkB bound on the Jmjd3 elements, as well as Jmjd3 
mRNA expression (Extended Data Fig. 1b–f). We then probed for Jmjd3 binding on specific 
oncogenic loci, previously shown to be important in T-ALL4. We found that Jmjd3 binding 
was highly enriched on the Hes1 promoter (Fig. 1d, left), depended on the activation of the 
Notch1 pathway and negatively correlated with H3K27m3 levels (Extended Data Fig. 1g, h).
Analyses of human leukemia cases2,23,24,25 showed that JMJD3 is more highly expressed in 
T-ALL compared to normal T cell progenitors23 and other types of leukemia24,25, similarly 
to the classical NOTCH1 target HES1 (Fig. 1e). Genes co-expressed with JMJD3 in human 
primary samples were found to exhibit loss of H3K27me3 during leukemia progression 
(Extended Data Fig. 1i), suggesting a connection between expression of JMJD3 and 
H3K27me3 levels on specific targets.
ChIP-Seq studies in T-ALL cells (CUTTL1) showed that JMJD3 binds to important 
NOTCH1 targets with oncogenic function (like HEY1, NRARP and HES1) (Fig. 1f). There 
is a statistically significant co-occupancy of JMJD3 with NOTCH126 (33% of top JMJD3 
peaks are occupied by NOTCH1, 6.9-fold enrichment over control, P<10−3), the NOTCH1 
partner RBPJk and the activating mark H3K4me326 (Extended Data Fig. 1j). The majority 
of JMJD3 binding sites were localized around the transcriptional start sites (TSSs) of genes 
(Fig. 1k) in a fashion similar to NOTCH126. These results suggest a key role for JMJD3 in 
oncogenic programs in T-ALL through interaction with NOTCH1. Protein 
immunoprecipitation studies in 293T cells as well as T-ALL lines showed that JMJD3 is 
part of the NOTCH1 transcriptional complex as it interacts directly with NOTCH1 and 
MAML1 whereas there was no NOTCH1 interaction with EZH2 or UTX (Extended Data 
Fig. 2a–c). As JMJD3 has been shown to be member of MLL complexes11, we tested 
whether it interacts with WDR5, a key subunit of MLL complex. We show here that JMJD3 
interacts with WDR5 (Extended Data Fig. 2b), suggesting a potential 
NOTCH1:JMJD3:MLL complex on target promoters.
To clarify the role of JMJD3 and UTX in the maintenance of leukemia, we performed 
genomic knockdown of JMJD3 in human T-ALL using two different short hairpin RNAs 
(shRNAs, Fig. 2a, b and Extended Data Fig 2d). Treatment with shJMJD3 but not shUTX 
affected the viability of leukemic cells, as shown by loss of representation studies and 
apoptosis assays, in contrast to myeloid leukemia lines used as controls (Fig. 2c Extended 
Data Fig. 2e, f). Expression of NOTCH1 targets was negatively affected by shJMJD3, 
accompanied by loss of JMJD3 and gain of H3K27me3 on their promoters (Extended Data 
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Fig. 3 a–e). Genome-wide expression analysis showed that more transcripts were 
significantly down-regulated than upregulated (749 protein-coding genes vs 297, Fig. 2d top 
panel and Extended Data Fig. 3f), in agreement with the JMJD3 role as a transcriptional 
activator. The down-regulated genes were found significantly enriched in genes that gained 
H3K27me3 on their promoters (Fig. 2d, bottom panel, P=1.015673e-07). shUTX downand 
up-regulated gene signatures were reversed in terms of gene numbers (46 down-regulated 
and 189 upregulated protein-coding genes, when compared to both shRenilla and shJMJD3). 
Intriguingly, JMJD3 expression itself is significantly upregulated upon UTX silencing 
(Extended Data 3a). Well-characterized NOTCH1 targets, as well as genes of the NFkB 
pathway were downregulated as part of the JMJD3 signature (Fig. 2d top and Extended Data 
Fig. 3g). These findings were confirmed using additional T-ALL lines with high levels of 
oncogenic NOTCH1 activity21 (Extended Data Fig. 3h, i). Subcutaneous (subq) or 
intravenous (i.v.) xenograft models of T-ALL cell lines (CUTLL1, CEM and P12) treated 
with either of the two shRNAs against JMJD3 (shJMJD3a and b) and transplanted into 
immuno-compromised mice (Rag2−/−γc−/−) showed a significant growth disadvantage (Fig. 
2e and Extended Data Fig. 4a–f). Interestingly, silencing of UTX leads to enhanced 
proliferation in many cases, suggesting a possible tumor suppressor function in vivo 
(Extended Data Figure 4g).
To examine the potential roles for Utx and Jmjd3 in the induction of T-ALL, we performed 
transplantation of bone marrow using hematopoietic stem cells from Utx and Jmjd3 
germiline knockout mice. Although female Utx−/− mice die at E9.5 due to defects in 
mesoderm development, a small fraction of male Utx−/Y mice survive to adulthood, as a 
result of compensation by Uty27. Despite the fact that T cell development is largely 
unaffected (Extended Data Fig. 5a, b) T-ALL kinetics were significantly faster on the 
Utx−/Y background, as determined by leukemic burden quantification in the peripheral blood 
and infiltration into the spleen (not shown) and liver (Fig. 3a–c and Extended Data Fig. 5c–
e). Moreover, mice succumb to the disease with significantly shorter latency in the absence 
of Utx compared to Utx+/y and Utx+/+ genotypes (Fig. 3d and Extended Data Fig. 5f–h). 
These experiments provide the first in vivo analysis of the tumor suppressor role of UTX in 
any tumor type.
To delineate the potential mechanism behind Utx action we performed gene expression 
analysis in sorted leukemic blasts of wild-type (Utx+/y/Utx+/y) or knockout (Utx−/y) 
background from the spleen or bone marrow (Fig. 3e). This analysis showed that Utx 
positively controls important tumor suppressor genes, like the Retinoblastoma binding 
protein 6 (Rbbp6), the inhibitor of the Notch1 pathway activity Fbxw7 and the PRC2 
member Suz12 whereas genes with oncogenic role in T-ALL-including Jmjd3-were up-
regulated (Fig. 3e and Extended Data Fig 5i). These studies strongly suggested that UTX 
might act as a tumor suppressor in human T-ALL. We thus screened a panel of primary 
pediatric T-ALL samples2 for genetic alterations of the UTX locus. Analysis of primary 
human samples of pediatric T-ALL using single nucleotide polymorphism (SNP) arrays 
identified two patients with focal deletions of the UTX locus (Fig. 3f). Further targeted 
sequencing in pediatric and adult T-ALL led to identification of six more patient cases with 
UTX mutations (Fig. 3g, Extended Data Fig. 5j, k and Supplementary File 2/Table 2) 
including in-frame deletions, missense (I598V) mutations and frameshift alterations. 
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Analysis of bone marrow remission genomic DNA confirmed the somatic origin of the UTX 
splice site mutation (Extended Data Fig. 5k). 7 out of 8 total alterations belong to male 
patients, further underlining the fact that UTX and UTY roles do not seem to be 
interchangeable. These genetic alterations are predicted to have an inactivating role19,20 and 
provide further evidence that UTX is a tumor suppressor in T-ALL. Indeed overexpression 
of UTX using a doxycycline-inducible lentiviral system in T-ALL cell lines (Extended Data 
Fig. 5l) led to suppression of tumor growth and significant increase of apoptosis (Extended 
Data Fig 5m).
Jmjd3−/− mice28, in turn, lack the catalytic domain of the Jmjd3 protein (Extended Data Fig. 
6a, b) and die perinatally28. Hematopoiesis and T cell development were largely unaffected 
by the absence of Jmjd3 (Extended Data Fig. 6c–h). Genetic ablation of Jmjd3 in T-ALL led 
to fewer leukemic blasts in the peripheral blood, significantly reduced leukemic infiltration 
into spleen and liver and improved survival rates in recipients (Extended Data Fig. 7a–f), 
consistent with an oncogenic role of Jmjd3. These striking phenotypes supported our 
previous in vitro and in vivo findings and led us to further explore the therapeutic potential 
of targeting Jmjd3 activity in T-ALL.
We next tested whether the small molecule GSKJ45 directed against JMJD3 and UTX 
(MALDI IC50s: JMJD3 18µM, UTX 56µM) can affect maintenance of the disease. We used 
GSKJ4 at its half-maximal inhibitory concentration (IC50, 2µM, Fig. 4a), to treat a panel of 
T-ALL lines. GSKJ4 significantly affected cell growth of T-ALL lines and primary human 
T-ALL cells (T-ALL1-3), leading to cell cycle arrest and increased apoptosis compared to 
control inhibitor-treated cells (Fig. 4b, Extended Data Fig. 8a–h). The first detectable 
changes started at 24h and we could see significant significantly altered phenotypes at 48 
and 72h (Fig. 4b and Extended Data Fig. 8a, i). These GSKJ4 effects appear to be connected 
to the JMJD3 demethylase activity as overexpression of the catalytically inactive JMJD3 did 
not rescue the phenotype (Extended Data Fig. 8j, k). Growth of myeloid leukemia cells, 
stromal cells and hematopoietic progenitor cells (Extended Data Fig. 8l, m) were unaffected 
by GSKJ4, demonstrating specificity of function. Mechanistically, we detected gene 
expression changes starting at 24h post-GSKJ4 treatment and significant changes were noted 
at 48h and 72h (Extended Data Fig. 8n) coupled to an increase of H3K27me3 levels at 
repressed genes (Extended Data Fig. 9a–c). NOTCH1 and JMJD3 DNA occupancy at 
specific NOTCH1 targets tested as well as total cellular levels of NOTCH1 and JMJD3 or 
chromatin H3K27me3 levels did not significantly change over treatment (Extended Data 
Fig. 9d–e).
Genome-wide studies identified 486 down-regulated genes after 72h of treatment with 
GSKJ4 (Fig 4c). There was significant overlap between shJMJD3 and GSKJ4 signatures for 
both down- (P = 4.88×10−44, Fig. 4d and Supplementary File 2/Table 3) and up-regulated 
genes (P = 2.57×10−20). On the contrary, the shUTX up-regulated gene signature 
significantly overlapped with the GSKJ4 down-regulated gene signature, Furthermore there 
was a significant overlap between genes upregulated in Utx knockout blasts and 
downregulated by GSKJ4 treatment (P=2.49×10−9, Fig.3e and 4d, and Supplementary File 
2/Table 3), suggesting once more that UTX and JMJD3 play opposing roles in T-ALL. 
Genome-wide study of H3K27me3 localization demonstrated that the GSKJ4 down-
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regulated genes experience gain of H3K27me3 upon GSKJ4 treatment and are marked by 
the presence of H3K4me3, NOTCH1 and JMJD3 in their promoters (Fig. 4c and Extended 
Data Fig. 1j). Well-characterized NOTCH1 and JMDJ3 targets are highlighted as 
representative examples of the GSKJ4.down/shJMJD3.down signature and show a 
significant gain of H3K27me3 upon GSKJ4 treatment (Fig. 4e and Extended Data Fig. 9f). 
UTX was not involved in the regulation of the oncogenic NOTCH1 targets as revealed by 
ChIP studies (Extended Data Fig. 9g).
We propose here targeting of JMJD3 as a novel therapy option for pediatric and adult T-
ALL. This proposal is based on recent studies2,4,29 that demonstrate that H3K27me3 
catalyzed by PRC2 complex plays a key role in T-ALL, through antagonism with oncogenic 
NOTCH1. We demonstrate here that NOTCH1-mediated JMJD3 recruitment on promoters 
could explain this antagonism (Extended Data Fig. 10, see also Supplementary File 1 for 
extended discussion). We propose that NOTCH1 recruitment could lead to PRC2 eviction 
due to active demethylation of H3K27 through the catalytic activity of JMJD3 and the 
recruitment of JMJD3 to target promoters. On the other hand, the reported increased levels 
of the activating H3K4me3 mark on a large fraction of NOTCH1 targets30 (Fig. 4f) can be 
explained by the fact that NOTCH1 has the ability to participate in MLL complexes 
(Extended Data Fig. 2 and 10). Moreover we demonstrate antitumorigenic activities of the 
GSKJ4 inhibitor5 and specificity for T-ALL cells. Obviously, we cannot exclude the 
possibility that GSKJ4 could potentially affect other important epigenetic modulators or 
signaling pathways. Nevertheless, we believe that the main action of this inhibitor in T-ALL 
is channeled through the inhibition of JMJD3 activity and propose that such compounds 
should be tested either as single drugs or in combination to standard chemotherapy.
Methods
Mice, Cell culture and primary cell samples
The knockout mouse models of Jmjd331 and Utx27 as well as the corresponding genotyping 
strategy have been described in published studies. All animals used in this study were 
treated according to IACUC protocols for Aifantis, Ferrando and Jaenisch laboratories. The 
human T-ALL CUTLL1132, P12-Ichikawa, Loucy, DND41, CEM, Jurkat and myeloid 
leukemia (THP1, HL-60) lines as well as the mouse T-ALL line (“720”)33 were all cultured 
in RPMI 1640 medium supplemented with 20% FBS and penicillin, streptomycin. All cell 
lines were being tested for the presence of mycoplasma and only mycoplasma-free lines 
were used for these studies. Primary human samples were collected by collaborating 
institutions with inform consent and analyzed under the supervision of the Columbia 
University Medical Center and St Jude Children’s Hospital Institutional Review Board. The 
primary cells treated with GSKJ4 inhibitor (for more information on these cells please check 
King et al.34) were cultured in MEMα medium plus 10% fetal bovine serum (StemCell 
Technologies, Inc. #06400), 10% human AB+ serum (Invitrogen), 1% penicillin/
streptomycin, 1% GlutaMAX, human IL-7 (R&D Systems; 10 ng/ml), human Flt3-ligand 
(Peprotech; 20 ng/ml), human SCF (Peprotech; 50 ng/ml) and insulin (Sigma; 20 nmol/L). 
Irradiated MS5 stromal cells overexpressing Delta-like 1 (DLL1) were used as a feeder 
layer, as previously described35.
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In vitro Drug Treatment and short-hairpin treatment and cell growth, apoptosis and cell 
cycle analysis
T-ALL cells were infected two times with the short-hairpin-expressing retroviruses and 
selected using puromycin. Expression studies took place at different time point during 
selection period and we present results from day 4 during selection. In order to calculate the 
IC50 of GSKJ4 (by GlaxoSmithKline)5 normalized to control inhibitor GSKJ5 
(GlaxoSmithKline), T-ALL lines were treated with different concentrations of the drug for 5 
days. For cell growth, annexin V staining and cell cycle analysis cell lines and primary 
cultures were treated with 2mM GSKJ4 and GSKJ5 for various amounts of time (24 h-72 h). 
Gamma secretase inhibitor (γSI, specifically Compound E (Alexis Biochemicals)) was used 
at 500 nM concentration for various amounts of time. For the cell cycle analysis, BrdU (10 
μM) was added for a 1 hr pulse, and incorporation into DNA was determined by using the 
BrdU Flow Kit (BD Biosciences). Apoptosis was studied by quantification of annexin V 
staining using the BD Biosciences kit and FACS according to standard protocol provided by 
the manufacturer. Doxycycline was used at 1µg/ml final concentration.
Intravenous and subcutaneous xenograft studies
Studies were conducted as before36. In both cases, CUTLL1, P12 or CEM T-ALL cells 
expressing luciferase (FUW-LUC) and the corresponding shRNA (shJMJD3, shUTX or 
shRenilla were used. For the intravenous studies, one million cells/type were injected retro-
orbitally in sublethally irradiated NOD-SCID female mice. For subcutaneous studies 1 
million cells/type were mixed with an equal volume of BD Matrigel basement membrane 
matrigel and injected into the flanks of NOD-SCID female mice. In both cases cell growth 
was monitored every 2 days using IVIS (Caliper, Perkin Elmer).
Transplantation for reconstitution of the hematopoietic system and for disease 
progression analysis
Fetal liver from Jmjd3+/+, Jmjd3+/− and Jmjd3−/− embryos (e13.5, Ly45.2 background) was 
provided by the Akira laboratory and 1 million of total (unfractionated) fetal liver was used 
for the reconstitution of the hematopoietic system of lethally irradiated recipients of Ly45.1 
background. Bone marrow was isolated from the recipients followed by isolation of cells of 
Ly45.2 background using sorting. 2.5×105 cells of total Ly45.2 bone marrow mononuclear 
cells were mixed with equal numbers of LY45.1 (wild type) bone marrow and transplanted 
into lethally irradiated recipients to study hematopoietic reconstitution in a competitive 
setting.
For the Utx+/+, Utx+/− and Utx−/Y (Ly45.2) background, 2.5×105 cells of total Ly45.2 bone 
marrow mononuclear cells were mixed with equal numbers of Ly45.1 (wild type) bone 
marrow and transplanted into lethally irradiated recipients to study hematopoietic 
reconstitution in a competitive setting similarly to Jmjd3 study.
In both cases reconstitution of the hematopoietic system was monitored with analysis of 
peripheral blood for the main hematopoietic lineages. Isolation and analysis of thymus and 
spleen was performed for some of the recipients at 3 months post transplantation.
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For analysis of leukemia progression, c-kit hematopoietic progenitors from the bone marrow 
of both Jmjd3- and Utx-knockout models, were magnetically selected (STEMCELL 
Technologies) using an antibody against CD-117 (c-Kit) and cultured overnight in the 
presence of 50 ng/ml SCF, 50 ng/ml Flt3 ligand, 10 ng/ml IL-3, and 10 ng/ml IL-6. Over-
expression of oncogenic NOTCH1 mutants (intracellular part of NOTCH1 (N1-IC) and 
DeltaE (N1-DE)) in bone marrow hematopoietic progenitors followed by transplantation 
into mouse recipients lead to development of T-ALL, characterized by the presence of 
leukemic blasts in the peripheral blood that can infiltrate the peripheral lymphoid organs, 
progressively leading to death of the animals (Extended Data Fig. 5c). The cells were 
infected with Notch1-IC or -DE (and GFP) expressing retroviruses twice (24h and 48h post 
c-kit selection). Viral transduction efficiency was determined by reporter fluorescence over 
a total period of 4 days, and total populations were transferred via retro-orbital injection into 
lethally irradiated congenic recipients along with 2.5×105 total (wild type) bone marrow 
mononuclear cells for hemogenic support. 45×104 GFP+ cells were transplanted in both 
Notch1-IC and –DE studies. Mantel-Cox test was used for the analysis of the survival data. 
No randomization/blinding method was used during these animal studies.
Antibodies, reagents, kits and virus production
The protein G-coated magnetic beads were purchased from Invitrogen. Antibodies used: 
monoclonal mouse H3K27me3 (histone H3 migrates at around 17kDa) (Abcam, ab6002), 
monoclonal mouse H3K27me1 antibody from Active Motif (61015), polyclonal rabbit 
H3K4me3 (Active Motif, 39159), rabbit polyclonal for NOTCH1 (the intracellular part of 
the protein migrates at around 110kDa), rabbit polyclonal JMJD3 (protein migrates at 
around 170kDa) (abgent, AP1022a (human) and AP1022b (mouse)) as well as polyclonal 
rabbit from Cell signaling (3457), rabbit polyclonal UTX (protein migrates at around 
160kDa) from abcam (ab36938) and Bethyl (A302-374A), rabbit polyclonal NF-kB (p65, 
protein migrates at around 65kDa Santa Cruz, sc-109 and sc-372) and control IgG (Santa 
Cruz (mouse (sc-2025) and rabbit (sc-2027)). All FACS antibodies were from eBioscience. 
All antibodies used have been tested and proven specific for the purposes used by 
companies/providers. The acid extraction protocol by abcam was used for the 
characterization of histone mark levels upon GSKJ4. To generate the virus, we infected 
293T cells with the plasmid expressing the corresponding hairpin (a miR-30-based 
system37) against JMJD3 (shJMJD3a: 
CAGGGAAGTTTCGAGAAGTCCTATAGTGAAGCCACAGA 
TGTATAGGACTCTCGAACTTCCCTT and shJMJD3b: 
ACACCAGCAGTAGCAACAGCA 
ATAGTGAAGCCACAGATGTATTGCTGTTGCTACTGCTGGTGG) and UTX 
(ACACAAGGTAG 
TCTACAGAATATAGTGAAGCCACAGATGTATATTCTGTAGACTA CCTTGTGG). 
We also used shRenilla (CTCGAGAAGGTATATTGCTGTTGACAG 
TGAGCGCAGGAATTATAATGCTTATCTATAGTGAAGCCACAGATGTATAGATAA
GCATTATAATTCCTATGCC TACTGCCTCGGAATTC) as control and the retroviral 
packaging plasmid. Viral supernatant was collected over a period of 72 h and used for 
transduction of T-ALL cells. The cells were infected twice and got selected with puromycin 
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starting 3 days after viral infection. Reporter fluorescence was used (FASC) for the 
quantification of hairpins.
Histopathology
Organs were harvested from the animals and immersion-fixed with 4% paraformaldehyde38 
overnight at 4° C. Samples were washed with phosphate buffered saline (PBS) 3 times for 1 
hour at room temperature and dehydrated in 70% ethanol. Samples were embedded in 
paraffin blocks. Sections (6 μm thick) were stained with hematoxylin and eosin (H & E) 
following the standard procedures. Peripheral blood smears were briefly fixed in methanol 
and stained with Wright-Giemsa solution (Fisher). Slides were rinsed with water, dried, 
mounted with Cytoseal 60 and coverslipped.
Protein Immunoprecipitation for Interaction Studies
For the interaction studies between NOTCH1 complex (NOTCH1, MAML1) with the 
epigenetic modulators (UTX, JMJD3, EZH2) we used standard protocols used elsewhere. In 
brief, cells were resuspended in TENT buffer (50mM Tris pH8.0, 5mM EDTA, 150mM 
NaCl and 0.05% (v/v) Tween-20) supplemented with the inhibitors at a concentration of 20 
million cells/ml buffer. Cell lysates were passed through 25G syringe (5×) and incubated on 
ice for 30’, followed by spin to remove cell debris (5’, full speed). The cleared lysate was 
precleared with beads for 1h at 4C to decrease non-specific binding and incubated overnight 
with the corresponding antibody-beads complexes. 5 micrograms antibody were used for 
3mg of extracts.
RNaseq Library Preparation and Analysis
Whole RNA was extracted from 1-5 million T-ALL (lines) cells or primary cells using the 
RNAeasy kit (Qiagen) according to the manufacturer’s protocol. Poly-A+ RNA was 
enriched using magnetic oligodT-containing beads (Invitrogen). cDNA preparation and 
strand-specific library construction was performed using the dUTP method as described in 
the past39. Libraries were sequenced on the Illumina HiS 2000 using 50bp single-read 
method.
Chromatin Immunoprecipitation and ChIP-Seq library preparation
ChIP experiments were performed as described in the past36. In brief, for analysis of histone 
marks we fixed the cells with 1% formaldehyde for 10 min at 25° C and lysed them by the 
addition of Nuclei Incubation Buffer (15 mM Tris pH 7.5, 60 mM KCl, 150 mM NaCl, 15 
mM MgCl2, 1 mM CaCl2, 250 mM Sucrose, 0.3% NP-40) and incubation at 4° C for 10’. 
The nuclei were washed once with Digest buffer (10 mM NaCl, 10 mM Tris pH 7.5, 3 mM 
MgCl2, 1 mM Cacl2) and we used micrococcal nuclease (USB) in digest buffer to generate 
mononucleosomal particles. The reaction was stopped with the addition of EDTA (20 mM). 
The nuclei were lysed in “nuclei lysis” buffer (50 mM Tris-HCl (pH 8.0), 10mM EDTA (pH 
8.0) and 1% SDS) followed by sonication using bioruptor (Diagenode) and chromatin was 
precleared by the addition of nine volumes of “IP dilution” buffer” (0.01% SDS, 1.1% 
Triton X-100, 1.2 mM EDTA (pH 8.0), 16.7 mM Tris-HCl pH 8.0 and 167 mM NaCl) and 
magnetic Dynal beads. 1% of the chromatin was kept as input. We coupled 2.5 mg antibody 
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with 25 mg antibody for 4 h in reaction buffer and the complex was added to precleared 
chromatin (equivalent of 105–106 cells, depending on the antibody) followed by overnight 
incubation at 4° C rotating. We washed the complexes bound on the beads using buffers 
with increasing salt concentration: once with “wash A” (20 mM Tris-HCl pH 8, 150 mM 
NaCl, 2 mM EDTA, 1% w/v Triton, 0.1% w/v SDS, once with “wash B” (20 mM Tris-HCl 
pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% w/v Triton, 0.1% w/v SDS), once with “wash C” 
(10 mM Tris-HCl pH8.0, 250 mM LiCl, 1 mM EDTA, 1% w/v Nonidet P-40, 1% w/v 
deoxycholic acid) and twice with TE, followed by treatment with RNAse, proteinase K, 
reverse the cross-links and precipitation of DNA using ethanol and glycogen.
For Jmjd3 ChIPs, the cells were fixed with 1% formaldehyde for 10 min at 25 °C and lysed 
on ice using 1ml “cell lysis” buffer (50 mM Hepes-KOH pH 7.5, 140 mM NaCl, 1 mM 
EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton X-100)/107 cells. We resuspended the 
pellet in 1ml buffer II (10 mM Tris-HCl pH 8, 200 mM NaCl, 1 mM EDTA pH 8 and 0.5 
mM EGTA)/107 cells. We further resuspended the nuclei in buffer III (10mM Tris-HCl pH 
8, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate and 0.5% n-
lauroylsarcosine) and sonicated with bioruptor (Diagenode) for 40’. Triton was added at a 
final concentration 1% and the chromatin preparation was precleared using magnetic beads. 
The antibody (5 mg) was coupled to the magnetic beads (50mls) as in the case of histone 
marks, the complex was added to the precleared chromatin (the equivalent of 10 million 
cells/reaction) and the reaction mix was incubated for 12–16 hours. The beads having the 
immunoprecipitated chromatin fragments were washed 8 times using “RIPA” buffer (50 
mM Hepes-KOH pH 7.6, 300 mM LiCl, 1mM EDTA, 1% NP-40 (IGEPAL), 0.7% Na-
Deoxycholate) and once with TE. The DNA was cleaned as in the case of the chromatin 
marks (see above). Libraries were generated as described before36, including end-repair, A-
tailing, adapter (Illumina Truseq system) ligation and PCR amplification of the libraries. 
Ampure XP beads (Beckman Coulter, A63880) were used for DNA cleaning in each step of 
the process.
Sequence analysis of primary samples
Sequencing and analysis of pediatric T-ALL samples was conducted as described in 
previously published studies2,40. In brief, sequencing of UTX in the pediatric T-ALL cohort 
was performed by PCR of whole genome amplified DNA, followed by sequencing using 
3730xl instruments (Applied Biosystems) as previously described41. Single nucleotide 
variations were detected by SNPdetector42 and PolyScan43, and validated by sequencing of 
both tumor and matched non-tumor samples. A total of 107 pediatric patients were screened 
including 64 cases with ETP ALL (25 females, 39 males) and 43 with ‘typical’ T-ALL (8 
females, 35 males). So, UTX mutations were detected in 4.7% of total population and in 
6.8% of the male population. No female samples were detected with UTX mutations. The 
two deletions and one of the frameshifts were found in patients with typical T-ALL, and the 
other two in ETPs.
Regarding the adult T-ALL case, all 83 samples were collected in the Eastern Cooperative 
Oncology Group (ECOG) clinical trials E299344 and C10403 and analyzed under the 
supervision of the Columbia University Medical Center IRB. Informed consent to use 
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leftover material for research purposes was obtained from all the patients at trial entry 
according to the Declaration of Helsinki. All exon sequences from UTX/KDM6A were 
amplified from genomic DNA by PCR and analyzed by direct dideoxynucleotide 
sequencing. Primer sequences used for KDM6A sequencing have been previously 
described19.
Data sources and computational tools
Patient and physiological T cell expression data was obtained from2,23,45. Human assembly 
version hg19/GRCh37 and ENSEMBL annotations release 69 were used for the RNA-
sequencing, ChIP-sequencing and data integration analyses. NOTCH1, RBPJ, H3K4me3 
and H3K27me3 ChIP-sequencing data in CUTLL1 were obtained from Wang et al.26 For 
the functional enrichment analysis, MSigDB46 version 3.1 was used. Bowtie47 version 
0.12.7 was used for alignment of sequenced reads. RNA-sequencing data analysis was 
performed using the DEGseq48. MACS49 version 2.0.10 was used for JMJD3 ChIP-
sequencing peak discovery in conjunction with the Irreproducible Discovery Rate (IDR) 
method50.. GenomicTools51 version 2.7.2 was used for performing genomic interval 
mathematical operations, genomic interval annotation, H3K27me3 ChIP-sequencing 
comparisons (GSKJ4 versus control) and ChIP-sequencing heatmap generation.
Expression analysis of primary samples
Processed T-ALL and B-ALL patient microarray expression data were downloaded from 
Zhang et al.,2 (GEO accession GSE33315), physiological T-cell expression data from Dik et 
al.,23 (GEO accession GSE22601), and AML expression data from Verhaak et al.,45 (GEO 
accession GSE6891). Data was first converted to logarithmic scale when necessary, and then 
quantile normalized across samples. Wilcoxon two-sided unpaired test per gene probe was 
used to determine significant differences between sample categories (T-ALL, B-ALL, AML 
and physiological T cells; Fig. 1e). A gene was considered significantly over-expressed in T-
ALL compared to the rest of the sample categories, if at least one of its associated probes 
was significantly over-expressed in T-ALL according to the statistical test.
Genes experiencing loss of H3K27me3 in TSS in our mouse NIC model compared to 
normal double positive (DP) mouse cells were obtained from our previous study36. 
Enrichment of human homologs of these genes in Jmjd3-correlating genes in the patient data 
described above was estimated as follows. First, Pearson’s correlation of Jmjd3 expression 
(separately for each Jmjd3 probe) against expression of each gene was computed. Then, the 
distribution of correlations of genes losing H3K27me3 (human homologs of the mouse 
genes) was compared to that of genes that do not lose H3K27me3 using Student’s T test 
(separately for each Jmjd3 probe, minimum p-value shown in the corresponding figure (1f)) 
or Wilcoxon one-sided unpaired test (not shown) yielding similar results. This analysis was 
repeated for NFκB1, NFκB2, REL, RELA, RELB, HES1, UTX, and EZH2 (Extended Data 
Fig. 1i).
Jmjd3 peak identification, characterization and overlap with published datasets
Jmjd3 ChIP-sequenced reads were aligned using bowtie (with default parameters, except for 
–m 1 so as to report only unique alignments) on human assembly version hg19. Peak 
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discovery was performed with MACS (version 2) using default parameters except for using 
a fragment size of 300bp estimated by Agilent 2100 Bioanalyzer. Sonicated input was used 
as a control for peak discovery. Then, we used the Irreproducible Discovery Rate (IDR) 
method50, guidelines and pipeline available for narrow peaks at (https://sites.google.com/
site/anshulkundaje/projects/idr) to determine highly reproducible peaks supported by both 
JMJD3 replicates.
Jmjd3 peaks were characterized according to their genome-wide distribution (Extended Data 
Fig. 1k) into: (a) 1kb TSS-flanking regions of transcript isoforms, (b) gene body regions 
(excluding any overlapping regions with (a)), and (c) upstream regions of minimum 10kb 
and up to a maximum of 100kb (excluding any overlapping regions with (a) or (b)).
Co-occurrence of JMJD3 peaks with H3K4me3, H3K27me3, NOTCH1 and RBPJ was 
computed as the percentage of such peaks (5,000 top-scoring peaks for each protein 
obtained from Wang et al.26; GEO accession GSE29600) that have some overlap with a 
JMJD3 peak. Statistical significance of these overlaps was determined using random 
resampling simulation (e.g. H3K4me3 peaks were randomly redistributed along the 
genome). As a control, we used the percentage of TSSs that have JMJD3 peaks (this is a 
rather conservative control since genome-wide JMJD3 occupancy is much lower, a result of 
JMJD3 being concentrated in TSSs), and, compared to this control, we obtain a ~7-fold 
enrichment of H3K4me3-JMJD3 (p-value <0.001 as determined by the random resampling 
scheme). Similar enrichments were obtained for NOTCH1-JMJD3 and RBPJ-JMJD3 co-
occurrence, whereas no significant enrichment was observed for H3K27me3-silenced or 
H3K4me1 enhancer-related regions (Extended Data Fig. 1j).
RNA-sequencing analysis
Differential gene expression analysis was performed for each matched knockdown vs 
control pairs, separately in each biological or technical replicate in each of three cell lines 
(CUTLL1, and CEM). Three types of comparisons were tested: (a) Jmjd3 knockdown vs 
renilla, (b) Jmjd3 knockdown vs Utx knockdown, and (c) Utx knockdown vs renilla. 
Analysis was performed using DEGseq48 on (a) matched knockdown-renilla replicates in 
separate DEGseq runs, and (b) all replicates on a combined DEGexp run. For the mouse 
(Utx knockout) samples, spleen and bone marrow from a wildtype male (referred to as 
animal #9) as well as spleen from a wildtype female animal (#10) were compared to spleen 
and bone marrow from a knockout male (#23) and spleen from another male knockout 
animal (#27) (see also our GEO entry, GSE50906). For illustration, scatter plots (Figures 2e, 
3e and Supplemental figures 5, 6) were created using values obtained from DEGseq analysis 
on merged biological and/or technical replicates. Gene RNA-sequencing FPKM values were 
computed using GenomicTools51. P-value cutoff for differential expression was set at 1e-5, 
with minimum absolute log2 fold-change at 0.5. However, all key results in this work (i.e. 
significance of overlaps of the various gene expression signatures demonstrating 
“contrasting roles” of JMJD3 and UTX) are robust to changes in these two parameters (data 
not shown).
The P-value of a gene set of size t (e.g. GSKJ4 down-regulated genes) containing k genes 
with a specific attribute (e.g. shJMJD3 down-regulation, or UTX knockout up-regulation) is 
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determined against the null hypothesis that k or more such genes could have been observed 
merely by chance in an equal-size gene set, randomly drawn from the entire reference set of 
genes of size N (i.e. all down-regulated, up- regulated and constant genes). This P-value is 
obtained by using the hypergeometric cumulative distribution with parameters N, t, k and n, 
where n is the number of genes possessing the attribute in the entire reference gene set of 
size N.
H3K27me3 gain/loss analysis
Jmjd3-affected (up- or down-regulated) genes were defined as genes whose expression is 
significantly differentially expressed in Jmjd3 knockdown compared to both renilla and Utx 
knockdown. Changes in Jmjd3 binding and the H3K27me3 mark around gene TSSs between 
inhibitor GSKJ4 and control GSKJ5 and were determined using GenomicTools 
(“genomic_apps peakdiff” tool) as described in previous published study36. Epigenetic 
changes between the treatment (shJMJD3 or GSKJ4) and control samples were determined 
by evaluating sliding windows across the genome using the following protocol. First, 
enriched ChIP-seq windows were identified separately for each of the two samples under 
comparison using a window-based approach and the binomial probability distribution to 
compare signal reads to control reads in each window. Subsequently, for each genomic 
window enriched in at least one of the two samples, the total number of reads was 
determined, and the window read counts were normalized using quantile normalization 
across biological replicates and samples before comparison. Finally, for each window, the 
fold-change between the two samples was calculated (GSKJ4 versus control and vice versa). 
To estimate the false discovery rate, the distribution of observed H3K27me3 fold-changes 
was compared against the distribution of fold-changes between replicates of the same 
treatment. This comparison was performed independently at different H3K27me3 read 
density levels to control for artificially high fold-changes due to low read counts in the 
denominator. Significant epigenetic changes are reported at 5% false discovery.
JMJD3, NOTCH1, H3K4me3 and H3K27me3 heatmaps were generated using 
GenomicTools (“genomic_apps heatmap” utility) over log-transformed read counts in 200nt 
non-overlapping bins of 4kb-flanked TSSs. Boxplots of H3K27me3 log2 fold-changes 
(GSKJ4 vs control) show the distribution of values in (a) JMJD3 targets, (b) commonly 
down-regulated genes upon shJMJD3 and GSKJ4, and (c) intersection of GSKJ4 up-
regulated with shJMJD3 up-regulated genes as a negative control. P-values are computed 
using a one-sided Wilcoxon unpaired test of (a) and (b) versus the control (c).
RNA-seq/ChIP-seq replicate reproducibilty
For RNA-seq experiments, we focused on the reproducibility of gene expression levels as 
measured by FPKMs. For each pair of replicates we computed the Spearman and Pearson 
correlations, as well as the Pearson correlation on log-transformed FPKM values. In general, 
Pearson correlations are much higher because higher values are dominant, and usually 
highly expressed genes tend to be more reproducible. Pearson correlation on log-
transformed values attempt to balance the expression distribution and allow contributions 
from genes of lower expression, and therefore provides a more realistic genome-wide 
reproducibility metric. Spearman correlations focus on ranking of gene expression and in 
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our experiments - in general - are a more conservative (i.e. lower) and consistent (lower 
variability across various settings, and when comparing different cell lines, i.e. CUTLL1 and 
CEM) estimate of reproducibility, therefore, for simplicity, we only report Spearman 
correlations.
For ChIP-seq “broad peak” experiments (H3K27me3) we also used Pearson, log-
transformed Pearson and Spearman correlations on (a) TSSs, and (b) all genome-wide 
peaks. As before, Spearman correlation was the most conservative and consistent estimate of 
reproducibility.
For ChIP-seq “narrow peak” experiments (JMJD3), in addition to TSS-based and genome-
based correlations, we used the Irreproducible Discovery Rate (IDR) method50, guidelines 
and pipeline available for narrow peaks at https://sites.google.com/site/anshulkundaje/
projects/idr. Apart from determining reproducibility, we also used the IDR method to 
determined high-confidence peaks supported by both JMJD3 replicates.
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Extended Data
Extended Data Figure 1. MJD3 is induced through activation of the NFkB pathway in a Notch1-
dependent mode in T-ALL and binds to NOTCH1 targets
a, Levels of p65 (Rela) protein in control T cells and T-ALL tumor. A representative sample 
of three mice is shown. b, Schematic representation of the Jmjd3 locus showing the Rela 
binding site (left panel) and ChIP analysis for p65 (Rela) binding on Jmjd3 locus in mouse 
control T and T-ALL tumor cells as well as T-ALL cells upon treatment with gSI which 
affects Notch1 levels (middle panel). NOTCH1 binding to this area upon γSI treatment in T-
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ALL cells is also shown (right panel). c, mRNA analysis for JMJD3 and HES1 levels upon 
γSI treatment in CUTLL1. The average of three independent studies is shown. d, e, 
Expression levels of JMJD3 transcript (d) and protein (e) upon treatment of human T-ALL 
lines (DND41 and CEM) with NEMO binding domain (NBD) inhibitor of the NFkB 
pathway. f, Jmjd3 levels in T-ALL cells upon inhibition of the NFkB pathway using a 
dominant negative form of IkBalpha (DN-IkBa). g, h, ChIP for Notch1 (g) and H3K27me3 
(h) on Hes1 promoter upon γSI treatment in murine T-ALL cells. In d and f–h the average 
of three studies is shown. In e a representative example of three studies is shown. i, Genes 
correlated with selected human genes (JMJD3, NFkB1, etc) were tested for enrichment in 
lossof-H3K27me3 genes during the transition to T-ALL in the mouse model. j, Overlap of 
JMJD3 peaks with peaks of important activating (H3K4me3 and H3K4me1) and repressive 
(H3K27me3) epigenetic marks as well as members of the NOTCH1 complex. The 
percentage of TSSs containing JMJD3 peaks is used as a conservative control, alternative to 
much lower genome-wide JMJD3 occupancy. k, Genome-wide distribution of JMJD3 peaks 
in human T-ALL.
Ntziachristos et al. Page 16
Nature. Author manuscript; available in PMC 2015 April 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Extended Data Figure 2. JMJD3 is vital for T-ALL growth through participation in NOTCH1 
transcriptional programs
a, NOTCH1 interaction analyses for JMJD3, MAML1 and WDR5 proteins in 293T cells. 
Interaction with JMJD3 was confirmed in a reciprocal way (right-most lane, IP using HA). 
b, Expression of JMJD3 and WDR5 in 293T cells, followed by immunoprecipitation using 
the HA antibody against HA-JMJD3. Flag antibody was used for the detection of both 
proteins. c, NOTCH1 interaction studies for JMJD3 and MAML1 proteins in mouse T-ALL 
cells expressing a Flag/Strep form of intracellular NOTCH1. Streptactin beads were used for 
NOTCH1 precipitation in the absence of detectable intracellular NOTCH1 and different 
antibodies were used for the detection of JMJD3, MAML1, EZH2 and UTX. Extracts from 
GFP-expressing cells were used as negative control. All experiments were repeated three 
times (biological replicates) and a representative example is shown. d, mRNA expression of 
JMJD3 and UTX upon treatment with short hairpin against JMJD3 and UTX. Expression 
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from two hairpins against JMJD3 and one hairpin against UTX and Renilla in CEM cells is 
shown. e, Effects on cell proliferation as measured by loss of GFP-expressing hairpin. 
HL-60 is an acute promyelocytic leukemia cell line (APL, subtype of acute myeloid 
leukemia (AML)), used as control in this study. In both lines the average of three 
representative studies is shown. f, Annexin V staining upon shJMJD3 and shRenilla in 
CUTLL1 (upper panel) and HPB-ALL (lower).
Extended Data Figure 3. JMJD3 binds to genes with important oncogenic function and is vital 
for T-ALL growth
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a, JMJD3-but not UTX-genetic inactivation impairs the expression of important oncogenic 
genes. NOTCH1, MYC and MAZ, as well as JMJD3 expression levels are shown. shUTX 
shows a significant up-regulation of JMJD3 compared to shRenilla (control) cells. The 
average of three studies is shown. b, Significant expression changes of NRARP transcript 
upon JMJD3 knockdown. c, ChIP for H3K27me3 on NRARP locus. d, e, Binding of JMJD3 
on NOTCH1 (d) and MAZ (e) promoter upon shJMJD3 and shRenilla (control). The 
average of three studies is shown. f, Numbers of up- and down-regulated genes are shown 
for shJMJD3 and shUTX compared to shRenilla. g, Scatterplot showing the expression 
levels of important genes in shJMJD3 and shUTX in CUTLL1 T-ALL cells. Emphasis is 
given to NOTCH1 pathway and apoptosis-related genes. This is a scatterplot representation 
of expression analysis comparing three independent studies for shJMJD3 and two for 
shUTX. h, i, Scatterplots showing the expression levels of important genes on shJMJD3 and 
shRenilla (h) and shUTX (i) in CCRF-CEM T-ALL cells. CEM exhibit increased NOTCH1 
levels through mutations in the heterodimerization (HD) domain of NOTCH1 and in the 
NOTCH1-associated ligase FBXW7. Emphasis is given to NOTCH1 pathway and 
apoptosis-related genes. This is a scatterplot representation of expression analysis comparing 
two studies for shJMJD3, two for shUTX and two for shRenilla.
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Extended Data Figure 4. In vivo studies of the role of JMJD3 in T-ALL using luciferase analysis 
of CEM, P12- and CUTLL1-based xenograft models in Rag γc−/− recipients
a, b, In vivo growth of CEM T-ALL cells in subq xenograft studies upon genomic ablation 
of JMJD3 and UTX (red and green circles denote shJMJD3 -expressing cells (two different 
hairpins), blue denotes shUTX–expressing cells and black circle denotes shRenilla -
expressing cells, a). One million CEM cells were injected into the animals and 
representative graphs from five mouse recipients and photo of a representative mouse in 
days 0 and 6 are shown. Representative graphs from five mouse recipients and the average 
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luciferase intensity in days 0 and 6 are shown (b). c, Representation of growth of CEM cells 
at different time points post transplantation in Subq studies (n=5). d, Comparison of in vivo 
cell growth in subcutaneous model of shJMJD3-, shUTX- and shRenilla expressing P12 
cells (n=5). One million P12 cells were injected into sublethally irradiated Rag γc−/− 
immunecompromised recipients and the mice were monitored every day for luciferase 
activity. Day zero is the first day that substantially detectable luciferase intensity was 
measured. The last day of the experiment was the day that either luciferase intensity reached 
saturation or the mice were euthanized for humanitarian reasons. Red and green circles 
denote shJMJD3 -expressing cells (two different hairpins, shJMJD3a and shJMJD3b 
correspondingly), blue denotes shUTX–expressing cells and black circle denotes shRenilla-
expressing cells). e, Monitoring change in luciferase intensity over a period of seven days in 
Subq xenograft model using CUTLL1 T-ALL cells (n=4). f, g, i.v. xenograft studies using 
CUTLL1 cells injected into sublethally irradiated Rag γ−/−c−/− immune-compromised 
recipients (n=8 or 6, as indicated in the figure). In all e–g cases half a million CUTLL1 cells 
were transplanted and the mice were monitored every day for luciferase activity.
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Extended Data Figure 5. Utx is a tumor suppressor and genetically inactivated in T-ALL Utx 
whereas is dispensable for physiological T cell development
a, b, Study of lymphoid development on Utx−/Y compared to Utx+/+ (or UTX+/Y, not 
shown) background. FACS analyses for CD4+ and CD8+ expression (a) and the relative 
proportions of CD4+, CD8+ double positive thymocytes across different genotypes (b) are 
shown. A representative example of three independent samples (biological replicates) is 
shown. c, Illustration of the transplantations scheme for the in vivo leukemia studies. d, e, T-
ALL progresses faster in the male knockout background for Utx (Utx−/y) compared to 
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female wildtype background (Utx+/+), in Notch1-IC/GFP, as it is demonstrated by white 
blood counts (d) in the peripheral blood as well as GFP+ cells representation upon 
transplantation of wild type progenitors (e) from female mice (Utx+/+) compared to the 
corresponding knock-out cells (Utx−/y). f, Survival study of the recipients for male wild-type 
(Utx+/Y, n=7) and knock-out (Utx−/Y, n=5) mice expressing Notch1-deltaE(ΔE)/GFP (the 
allele with the weaker oncogenic action compared to Notch1-IC). g, h, Survival analysis of 
recipients upon transplantation of wild type progenitors from female mice (Utx+/+) 
compared to the corresponding knock-out cells (Utx−/y) infected with N1-IC (g) or N1-ΔE 
(h). i, qPCR validation of expression levels of one down-regulated (Suz12) and one up-
regulated (Il7ra) gene in Utx−/Y (compared to UTX+/Y). The average of three independent 
samples/studies is presented. j, Targeted Sanger sequencing in pediatric led to identification 
of three cases with frameshift mutations. The positions of mutations are indicated by dashed 
lines in the electropherograms. k, Identification of one in-frame deletion (p.A14_A17del, 
#1, top panel), one splice acceptor site (#2, second panel) and one missense mutation (#3, 
third panel) in adult T-ALL. #4 is an adult T-ALL case with wild-type UTX (control, bottom 
panel). Mutations are indicated by red-colored characters. l, Levels of UTX in CUTLL1 T-
ALL cells in the absence (−dox) or presence (+dox) of doxycycline. m, n, Apoptosis 
analysis through measuring annexin-V staining using control LacZ-expressing and UTX-
expressing CUTLL1 in the absence (−dox) or presence (+dox) of doxycycline. 
Representative plots (l, n) as well as average representation (l, m) of three independent 
experiments are shown.
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Extended Data Figure 6. Physiological development of the hematopoietic system in the absence 
of Jmjd3
a, b, Targeting scheme for the generation of Jmjd3−/− allele (a) and PCR-based 
quantification of the wild-type and mutant transcripts (b) using a specific primer set for the 
3’ end of Jmjd3 cDNA. c, d, Analysis of the fetal liver for lineage markers (c) as well as 
bone marrow (d) of recipients for hematopoietic progenitors (lineage−, c-kit+, sca+ (LSK) 
population) for the Jmjd3+/+ and Jmjd3−/− genotypes. Representative plots of three 
independent experiments are shown. e–g, Analysis of major thymic subsets in Jmjd3+/+ 
(n=7) and Jmjd3−/− (n=7). Schematic representation of FACS analysis performed (e). 
Relative proportions of major cell populations in the thymi of Jmjd3+/+ and Jmjd3−/− 
background (f). mRNA expression of Jmjd3 gene in different stages of thymic development 
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(g). h, and expression of Notch1 target (like Hes1, n=7) in CD4+/CD8+ double positive and 
CD4− CD8−CD25+ lymphocyte progenitor cells. Representative plots (e) as well as average 
representation (g, h) of seven independent thymi are shown.
Extended Data Figure 7. JMJD3 is necessary for disease initiation in an animal model of T-ALL
Initiation of the disease was studied using a transplantation scheme of c-kit hematopoietic 
progenitors. a, b, Blood analysis of the recipients for Notch1-IC/GFP leukemic blasts 
(Jmjd3+/− (n=8) and Jmjd3−/− (n=8), a) and white blood cells (WBC, Jmjd3+/− (n=4) and 
Jmjd3−/− (n=6), b). Comparison of the organs size (c) and histochemistry (H&E) (d) and 
FACS-based (e) analysis of the leukemic infiltration in the spleen. f, Survival studies of 
recipients. Eight recipients for Jmjd3+/− and eight for Jmjd3−/− background were used in 
panels c–f.
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Extended Data Figure 8. GSKJ4 inhibitor induces apoptosis and cell cycle arrest of T-ALL-but 
not myeloid leukemia or physiological LSK-cells
a, Effect of GSKJ4 (at 2µM concentration) on a panel of T-ALL and myeloid lines. The 
average of three representative studies is shown. b–d, Effects on cell growth (b), apoptosis 
(c) and cell cycle (d) in three primary T-ALL lines. The average of three representative 
studies is shown. e, f, Measurement of apoptosis (e, n=3) and cell cycle effects (f, 
representative study of three experiments) in CUTLL1 cells 72 hours post treatment with the 
inhibitor. g, h, Apoptosis assays using Annexin V staining of CEM (g) after a period of 72 
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hours of treatment and measuring caspase 7/9 activity upon treatment of CUTLL1 (h) T-
ALL cells with GSKJ5 and GSKJ4 over a period of 24 hours. i, Timecourse studies of 
Annexin V (upper panel) and cell cycle (lower panel) analysis of CUTLL1 cells over a 
period of 72h during GSKJ4 treatment according to the scheme on top of the figure. j, 
Expression of wild-type and catalytic mutant of JMJD3 in T-ALL (CEM) cells. k, Cell 
growth analysis of T-ALL cells overexpressing wild type and catalytically mutant JMJD3 
upon GSJ4 treatment over a period of 72h. Average representation of three independent 
experiments is shown. l, Cell growth of LSK upon treatment with control (2uM) and 
different concentrations of GSKJ4 inhibitor. m, Annexin V staining of THP1 cells after a 
period of 72 hours of GSKJ4 and GSKJ5 (control) treatment at 2mM concentration. Average 
representation of three independent experiments is shown. n, mRNA levels are shown for 
three classical NOTCH1 targets (HEY1, NRARP and NOTCH1) over a period of 72h during 
GSKJ4 treatment. Average representation of three independent experiments is shown.
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Extended Data Figure 9. GSKJ4 treatment leads to increased H3K27me3 levels on NOTCH1 
targets through specific inhibition of JMJD3 activity
Analysis of the promoter area of HEY1 (a), NRARP (b) and NOTCH1 (c) for H3K27me3, 
H3K27me1, NOTCH1 and JMJD3 enrichment over a period of 24h during GSKJ4 
treatment. Average representation of three independent experiments is shown. d, Analysis of 
total protein extracts from CUTLL1 cells for JMJD3 and NOTCH1. e, Analysis of 
chromatin fraction from CUTLL1 cells for the repressive mark H3K27me3, the activating 
marks H3K27me1 and H3K4me3 as well as total histone H3 levels. Representative plots of 
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three independent experiments are shown. f, Snapshots of GSKJ4-associated H3K27me3 
changes in major NOTCH1 and JMJD3 targets. g, ChIP-qPCR analyses for UTX binding on 
NOTCH1 targets HEY1, NRARP and NOTCH1 (RBBP6 is used as positive control). The 
average of three independent experiments is shown.
Extended Data Figure 10. JMJD3 as a pivotal factor in NOTCH1-mediated oncogenic activation 
in T cell leukemia
a, Schematic representation of the H3K27me3 writer (polycomb complex, right panel) and 
eraser JMJD3 (left panel). EZH2 entails the catalytic subunit of the complex through its SET 
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domain, whereas EED subunit recognizes the H3K27me3 mark and helps polycomb 
binding. JmjC domain activity is inhibited by the small molecule inhibitor GSKJ4. b, Main 
notion of the key role of JMJD3 in the NOTCH1 transcriptional complex’ Before activation 
of the NOTCH1 signaling pathway the promoters of classical NOTCH1 targets are bound by 
RBBJk together with components of the co-repressor complexes and poycomb repressive 
complex 2 (PRC2), leading to low gene expression. After binding of NOTCH1 and its co-
activator MAML1 the genes are activated through recruitment of JMJD3 and MLL complex, 
with simultaneous eviction of PRC2, which leads to demethylation of H3K27me3 and 
methylation of H3K4me3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. JMJD3 is highly expressed in T-ALL and controls expression of important oncogenic 
targets
a, Size comparison of the spleens (left) and hematoxylin and eosin staining of the liver 
(right) of healthy (WT, top) and leukemic (T-ALL, bottom) mice. Arrows denote leukemic 
infiltration in the liver of T-ALL mouse. b, c, Protein (b) and transcript (c) levels of Jmjd3 
and Utx demethylases in control T cells (CD4+/CD8+ thymocytes) and T-ALL. 
Representative sample (a, b) or the average (c) of three mice is shown. d, ChIP for Jmjd3 on 
Hes1 promoter in control T cells and T-ALL (left panel) and upon γSI treatment in T-ALL 
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(right panel) (n=3). e, Expression analysis of JMJD3 and HES1 amongst 595 primary 
samples of T (83 samples)- and B (23)-cell Leukemia, Myeloid leukemia (537) as well as 
physiological T cell subsets (24)23. P–values (Wilcoxon test), JMJD3: T-ALL vs T cells: 
4.0×10−6, T-ALL vs AML: 1.1×10−13, T-ALL vs B-ALL: 2.2×10−5. Hes1: T-ALL vs T 
cells: 3.7×10−4, T-ALL vs AML: 3.5×10−43, T-ALL vs B-ALL: 1.3×10−6. f, Snapshots of 
JMJD3 binding in human T-ALL. Three NOTCH1 targets and the Interferon beta (IFNβ) 
gene (negative control) are shown.
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Figure 2. Dissecting the oncogenic role of JMJD3 in T-ALL
Protein levels of JMJD3 (a) and UTX (b) in T-ALL cells (CUTLL1), expressing 
corresponding shRNAs against the two demethylases. Representative plots of three 
independent studies (biological replicates) are shown. c, Effects on T-ALL cell proliferation 
as measured by loss of GFP-expressing hairpin. In all lines the average of three 
representative studies is shown. d, Differential expression analysis upon knockdown of 
JMJD3 in T-ALL (top panel). Loci of downregulated genes exhibit an increase of 
H3K27me3 (red dots in the bottom panel), while upregulated genes exhibit decrease in 
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H3K27me3. Representation of three independent studies is shown. e, In vivo growth of P12 
T-ALL cells in i.v. xenograft studies upon genomic ablation of JMJD3 and Renilla (control). 
One million P12 cells were injected into seven animals. Sublethally irradiated Rag γc−/− 
immuno-compromised mice were used as recipients and transplantation leukemic cell 
growth is compared to the baseline (day zero). Day zero is the first day when substantially 
detectable luciferase intensity was measured. The last day of the experiment was the day that 
either luciferase intensity reached saturation or the mice were euthanized for humanitarian 
reasons.
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Figure 3. UTX demethylase acts as a tumor suppressor in T-ALL
a–c, Monitoring initiation and progression of T cell leukemia in a Notch1-overexpressing 
model of T-ALL. Leukemic blast (expressed as NOTCH1-IC/GFP positive cells) in the 
peripheral blood (a), blood smear analysis (b) and leukemic infiltration in the liver (c) of 
male wild-type (Utx+/+, n=10) and knock-out (Utx−/Y, n=6) mice is shown. d, Survival 
studies of the mouse recipients transplanted with hematopoietic progenitors of the wild-type 
(Utx+/Y, n=10) and knock-out (Utx−/Y, n=6) background expressing N1-IC model are 
shown. e, Scatterplot representation summarizing the major genomewide expression 
differences between T-ALL tumors of wild-type (Utx+/Y) and knock-out (Utx−/Y) 
background. RNA sequencing was performed using three pairs of wild-type and Utx 
knockout NOTCH1-IC tumors (spleen/bone marrow). f, g, Analysis of genetic status of 
UTX (KDM6A) locus in pediatric T cell leukemia (n=107). SNP6.0 microarrays (f) for 
genomic deletions. Illustration of the human UTX protein (g) depicting three frameshift 
mutations in pediatric T-ALL (grey circle) as well as one in-frame deletion (p.A14_A17del), 
one splice acceptor site mutation and one missense mutation in adult T-ALL (white circle), 
as identified by targeted Sanger sequencing. The Jumonji domain (JmjC) and the 
tetratricopeptide repeats are shown.
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Figure 4. Pharmacological targeting of T-ALL through specific inhibition of the JMJD3 
demethylase activity
a, Dose dependent effect of GSKJ4 inhibitor (normalized to control inhibitor, GSKJ55) on 
CUTLL1 cells proliferation. b, Effect of GSKJ4 (at 2µM) on CUTLL1 T-ALL cells. c, 
Heatmap representation of GSKJ4-associated changes in gene expression (left panel, three 
biological replicates) and H3K27me3 changes (right) of 486 significantly down-regulated 
coding transcripts over a period of 72h. Middle: Occupancy of JMJD3, NOTCH1 and 
H3K4me3 marks in respective 4kb-flanked TSS regions. d, Comparison of the shJMJD3 and 
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shUTX expression-based signatures with the GSKJ4-induced expression changes. Note the 
highly significant overlap between genes down-regulated in shJMJD3 and GSKJ4 including 
HEY1, NRARP and NOTCH1. e, Box-plots representing H3K27me3 changes upon GSKJ4 
treatment in JMJD3 targets as well as in the commonly down-regulated genes in shJMJD3 
and GSKJ4. Genes up-regulated in shJMJD3 and downregulated upon GSKJ4 treatment are 
negative control. P-values: JMJD3targets vs GSKJ4.down/shJMJD3.up: 2.7×10−33, 
GSKJ4.down/shJMJD3.down vs GSKJ4.up/shJMJD3.up: 4.4×10−15.
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